Publications

2018

- Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 22. pii: S0140-6736(18)30475-6. doi: 10.1016/S0140-6736(18)30475-6. [Epub ahead of print]
- Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators (J Pelletier, Membre). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 Mar 12. pii: S1474-4422(18)30069-3. doi: 10.1016/S1474-4422(18)30069-3. [Epub ahead of print]
- Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie, M Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, and Marignier R. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018.
- Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P,  Hutchinson M, D’Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Trojano M, Patti F, Vukusic S, for the PRIMS and POPARTMUS. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Mult Scler J 2018. In Press.
- Van Obberghen E, Mchinda S, le Troter A, Prevost VH, Viout P, Guye M, Varma G, Alsop DC, Ranjeva JP, Pelletier J, Girard OM, Duhamel G. Evaluation of the sensitivity of inhomogeneous Magnetization Transfer (ihMT) MRI for Multiple Sclerosis. AJNR Am J Neuroradiol. 2018 Feb 22. doi: 10.3174/ajnr.A5563.

2017

- Mchinda S, Varma G, Prevost VH, Le Troter A, Rapacchi S, Guye M, Pelletier J, Ranjeva JP, Alsop DC, Duhamel G, Girard OM. Whole brain inhomogeneous magnetization transfer (ihMT) imaging: Sensitivity enhancement within a steady-state gradient echo sequence. Magn Reson Med. 2017 Sep 23. doi: 10.1002/mrm.26907.
- De Looze C, Moreau N, Renié L, Kelly F, Ghio A, Rico A, Audoin B, Viallet F, Pelletier J and Petrone C. Effects of cognitive impairment on prosodic parameters of speech production planning in multiple sclerosis. J Neuropsychol. 2017 May 24. doi: 10.1111/jnp.12127.
- Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, Smadja D, Marignier R; Francophone Society of Multiple Sclerosis and OFSEP investigators (J. Pelletier, Membre). Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018 Feb 17. doi: 10.1007/s00415-018-8771-5.
- Meunier B, Rico A, Seguier J, Boutiere C, Ebbo M, Harle JR, Schleinitz N, Pelletier J. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler J. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
- Donadieu M, Le Fur Y, Maarouf A, Gherib S, Ridley B, Pini L, Rapacchi S, Confort-Gouny S, Guye M, Schad LR, Maudsley AA, Pelletier J, Audoin B, Zaaraoui W, Ranjeva JP. Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study. Mult Scler J 2017:1352458517736146.
- Wybrecht D, Reuter F, Pariollaud F, Zaaraoui W, Le Troter A, Rico A, Crespy L, Confort-Gouny S, Soulier E, Guye M, Ranjeva JP, Pelletier J and1.6+ Audoin B. New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: a ten-year longitudinal study. Plos One 2017;17;12(11):e0184650.
- Boutière C, Rey C, Zaaraoui W, Le Troter A, Rico A, Crespy L, Achard S, Reuter F, Pariollaud F, Wirsich J, Asquinazi P, Confort-Gouny S, Soulier E, Guye M, Pelletier J, Ranjeva JP, Audoin B. Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices. Mult Scler J. 2017;23(6):855-863.
- Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; BIONAT, BEST-MS and SFSEP network. MMP9 is decreased in natalizumab-treated MS patients at risk for PML. Ann Neurol. 2017; 82(2):186-195.
- Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group (J. Pelletier, Membre). Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017;82(1):20-29.
- Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C. Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. Neurol Neuroimmunol Neuroinflamm. 2017; 14;4(3):e346.
- Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D. Radiologically isolated syndrome in children: Clinical and radiologic outcomes. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e395.
- Maarouf A, Audoin B, Pariollaud F, Gherib S, Rico A, Soulier E; Confort-Gouny S, Guye M, Schad L, Pelletier J, Ranjeva JP, Zaaraoui W. Neuronal dysfunction better explains cognition than neuronal loss in early MS: a 23Na MRI study. Neurology. 2017;88(3):289-295.
- Michel P, Baumstarck K, Boyer L, Fernandez O, Flachenecker P, Pelletier J, Loundou A, Ghattas B, Auquier P; MusiQoL Study Group. Defining Quality of Life Levels to Enhance Clinical Interpretation in Multiple Sclerosis: Application of a Novel Clustering Method. Med Care. 2017;55(1):e1-e8.
- Planche V, Moisset X, Morello R, Dumont E, Gibelin M, Charré-Morin J, Saubusse A, Mondou A, Reuter F, Defer G, Pelletier J, Brochet B, Clavelou P. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study. J Neurol Sci. 2017;382:148-154.
- Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators (J. Pelletier, Membre). Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS One. 2017;12(1):e0168834.
- Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017 Sep;23(10):1377-1384.
- Doche E, Lecocq A, Maarouf A, Duhamel G, Soulier E, Confort-Gouny S, Rico A, Guye M, Audoin B, Pelletier J, Ranjeva JP, Zaaraoui W. Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. J Neuroradiol. 2017;44(2):158-164.

2016

- Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP (J. Pelletier, Membre). Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler J. 2016;22(7):955-9.
- Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP) (J. Pelletier, Membre). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler J. 2017;23(10):1377-1384.
- Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, Lubetzki C, Confavreux C; TYSEDMUS and OFSEP Group (J. Pelletier, Membre). Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e297.
- Kalson-Ray S, Edan G, Leray E; SURVIMUS Study Group (J. Pelletier, Membre). An excessive risk of suicide may no longer be a reality for multiple sclerosis patients. Mult Scler. 2017;23(6):864-871.
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators (J. Pelletier, Membre). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220.
- Enzinger C, Pinter D, Rocca MA, De Luca J, Sastre-Garriga J, Audoin B, Filippi M. Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. Mult Scler. 2016 Mar;22(3):269-78. doi: 10.1177/1352458515619781. Epub 2015 Dec 18. Review. PubMed PMID: 26683590.
- Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology. 2016;87(23):2491-2494.
- Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J (MS-SPI study group). MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler J. 2016;22(13):1719-1731.
- Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP (J. Pelletier, Membre), BIONAT Network. RISC. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. J Neurol Sci. 2016;368:334-6.
- Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group (J. Pelletier Membre). The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87(10):978-87.
- Faivre A, Robinet E, Guye M, Rousseau C, Maarouf A, Le Troter A, Zaaraoui W, Rico A, Crespy L, Soulier E, Confort-Gouny S, Pelletier J, Achard S, Ranjeva JP, Audoin B. Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study. Mult Scler J. 2016;22(13):1695-1708.
- Maarouf A, Ferré JC, Zaaraoui W, Le Troter A, Bannier E, Berry I, Guye M, Pierot L, Barillot C, Pelletier J, Tourbah A, Edan G, Audoin B, Ranjeva JP. Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome. Mult Scler J. 2016;22(8):1032-9.
- Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. J Neurol Sci. 2016; 363:69-76.
- Michel P, Baumstarck K, Ghattas B, Pelletier J, Loundou A, Boucekine M, Auquier P, Boyer L. A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT. Medicine (Baltimore). 2016; 95(14):e3068.
- O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas; Teriflunomide Multiple Sclerosis Oral TEMSO Trial Group and the MRI-AC in Houston Texas (J. Pelletier Membre). Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920-30.
- Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators (J. Pelletier, Membre). Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075-84.
- Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87(5):468-75.
- Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology. 2016;86(8):771-8.
- Donadieu M, Le Fur Y, Lecocq A, Maudsley AA, Gherib S, Soulier E, Confort-Gouny S, Pariollaud F, Ranjeva MP, Pelletier J, Guye M, Zaaraoui W, Audoin B, Ranjeva JP. Metabolic voxel-based analysis of the complete human brain using fast 3D-MRSI: Proof of concept in multiple sclerosis. J Magn Reson Imaging. 2016; 44(2):411-9.
- Taieb G, Duran-Peña A, de Chamfleur NM, Moulignier A, Thouvenot E, Allou T, Lacour A, Hoang-Xuan K, Pelletier J, Labauge P. Punctate and curvilinear gadolinium enhancing lesions in the brain: a practical approach. Neuroradiology. 2016; 58(3):221-35.

2015

- Michel P, Auquier P, Baumstarck K, Pelletier J, Loundou A, Ghattas B, Boyer L. Development of a cross-cultural item bank for measuring quality of life related to mental health in multiple sclerosis patients. Qual Life Res. 2015;24(9):2261-71.
- Michel P, Baumstarck K,  Auquier P,  Pelletier J, Loundou A, Boucekine M, Ghattas B, Boyer L. Development of a multidimensional computerized adaptive test for measuring quality of life for patients with multiple sclerosis: the MuSiQoL-MCAT.  Qual Life Res. 2015;24(S1):35-38.
- Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, Sèze Jd, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G. Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLoS One. 2015;10(7):e0132033.
- Faivre A, Rico A, Zaaraoui W, Reuter F, Confort-Gouny S, Guye M, Pelletier J, Ranjeva JP, Audoin B. Brain functional plasticity at rest and during action in multiple sclerosis patients. J Clin Neurosci. 2015; 22(9):1438-43.
- Baumstarck K, Pelletier J, Boucekine M, Auquier P. MusiQoL study group. Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study. Rev Neurol (Paris). 2015;171(2):173-80.
- Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick J, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño J, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez A, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr K, Galimberti D, Rejdak K, Lycke J, Frederiksen J, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier B, Hartung H, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar L, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan S, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler. 2015;21(8):1013-24.
- Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015;21(8):1025-35.
- Michel P, Baumstarck K, Boyer L, Fernandez O, Flachenecker P, Pelletier J, Loundou A, Ghattas B, Auquier P; on behalf of the MusiQoL Study Group. Defining Quality of Life Levels to Enhance Clinical Interpretation in Multiple Sclerosis: Application of a Novel Clustering Method. Med Care. 2015;24(9):2261-71.
- Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. The International Multiple Sclerosis Genetics Consortium (IMSGC, J Pelletier, Membre).The Psychiatric Genomics Consortium (PGC) Bipolar Disorder and Schizophrenia Work Groups. Mol Psychiatry. 2015;20(2):207-14.
- Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. J Neurol. 2015;262(7):1637-45.
- Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; For the CONFIRM study investigators (J. Pelletier, Membre). Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015; 17;84(11):1145-52.
- Caucheteux N, Maarouf A, Genevray M, Leray E, Deschamps R, Chaunu MP, Daelman L, Ferré JC, Gout O, Pelletier J, Pierot L, Edan G, Tourbah A. Criteria improving multiple sclerosis diagnosis at the first MRI. J Neurol. 2015;262(4):979-87.
- Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson J, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche J, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud D, Ouallet J, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Louis Defer G, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau J, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P. Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. Brain. 2015;138(2):284-92.
- Baumstarck K, Pelletier J, Boucekine M, Auquier P. MusiQoL study group. Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study. Rev Neurol (Paris). 2015; 171(2):173-80.
- Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21. PubMed PMID: 26194198.

2014

- Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP) (J Pelletier, membre). Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014 Mar 5;9(3):e90509.
- Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; for the ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 ; 13(7):657-65.
- Crimi A, Commowick O, Maarouf A, Pelletier J, Ferré JC, Bannier E, Tourbah A, Berry I, Ranjeva JP, Edan G, Barillot C. Predictive Value of Imaging Markers at Multiple Sclerosis Disease Onset Based on Gadolinium- and USPIO-Enhanced MRI and Machine Learning. PLoS One. 2014;9(4):e93024.
- Baumstarck K, Boucekine M, Boyer L, Aghababian V, Parola N, Reuter F, Loundou A, Lançon C, Pelletier J and1.5+ Auquier P. Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. BMC Neurol. 2014;14(1):78.
- Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; for the Club Francophone de la Sclérose en Plaques Investigators. Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study. JAMA Neurol. 2014;71(4):436-41.
- Khatri BO,  Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, vonRosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA, on behalf of the TRANSFORMS Study Group . Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). Multiple Sclerosis and Related Disorders. 2014.  3(3): 355–63.
- Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, Nicolino M, Simon A, Viallard JF, Costedoat-Chalumeau N, Courcoux MF, Pondarré C, Hilliquin P, Chatelus E, Foltz V, Guillaume S, Rossignol M, Abenhaim L; the PGRx-AID Study Group (J. Pelletier, membre). Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398-408.
- Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; on behalf of the ALLEGRO Study Group (J. Pelletier, membre). Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry.2014;85(8):851-8.
- Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT network, and CFSEP. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol. 2014;21(1):40-8.
- Maarouf A, Audoin B, Konstandin S, Rico A, Soulier E, Reuter F, Le Troter A, Confort-Gouny S, Cozzone PJ, Guye M, Schad LR, Pelletier J, Ranjeva JP, ZaaraouiW. Topography of brain sodium accumulation in progressive multiple sclerosis. MAGMA 2014;27(1):53-62.

2012 -2013

- Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One. 2013;8(10):e75416.
- Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Association of multiple sclerosis susceptibility variants and early attack location in the CNS. PLoS One. 2013;8(10):e75565.
- Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group (J Pelletier, membre). Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013;19(10):1310-9.
- Baumstarck K, Butzkueven H, Fernández O, Flachenecker P, Stecchi S, Idiman E, Pelletier J, Boucekine M, Auquier P. Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. Health Qual Life Outcomes. 2013;11(1):127.
- Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, Pelletier J, Eckert B, Häring DA, Francis G. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol. 2013;60(8):2023-32.
- Baumstarck K, Boucekine M, Klemina I, Reuter F, Aghababian V, Loundou A, Pelletier J and Auquier P. What is the relevance of quality of life assessment for patients with attention impairment? Health Qual Life Outcomes.2013, 11:70.
- Baumstarck K, Pelletier J, Butzkueven H, Fernández O, Flachenecker P, Idiman E, Stecchi S, Boucekine M, Auquier P; for the MusiQoL study group. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2013 Jun;20(6):907-14, e78-9.
- Boucekine M, Loundou A, Baumstarck K, Minaya-Flores P, Pelletier J, Ghattas B, Auquier P. Using the random forest method to detect a response shift in the quality of life of multiple sclerosis patients: a cohort study. BMC Med Res Methodol. 2013;13(1):20-24.
- Baumstarck K, Reuter F, Boucekine M, Aghababian V, Klemina I, Loundou A, Pelletier J and Auquier P. Relevance of quality of life assessment for multiple sclerosis patients with memory impairment. PLoS One. 2012;7(12):e50056.
- Faivre A, Rico A, Zaaraoui W, Crespy L, Reuter F, Wybrecht D, Soulier E, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP, Audoin B. Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. Mult Scler. 2012, 18(9):1251-8.
- Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT and CONFIRM Study Investigators(J. Pelletier, membre).Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97.
- Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS; for the Teriflunomide Multiple Sclerosis Trial Group (J. Pelletier, membre). Pre-specified subgroup analyses of a placebo-controlled hase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012, 18(11):1625-1632.
- Zaaraoui W, Konstandin S, Audoin B, Nagel AM, Rico A, Malikova I, Soulier E, Viout P, Confort-Gouny S, Cozzone PJ, Pelletier J, Schad LR, Ranjeva JP. Distribution of Brain Sodium Accumulation Correlates with Disability in Multiple Sclerosis: A Cross-sectional 23Na MR Imaging Study. Radiology. 2012;264(3):859-67.
- Taieb G, Duflos C, Renard D, Audoin B, Kaphan E, Pelletier J, Limousin N, Tranchant C, Kremer S, de Sèze J, Lefaucheur R, Maltête D, Brassat D, Clanet M, Desbordes P, Thouvenot E, Magy L, Vincent T, Faillie JL, de Champfleur N, Castelnovo G, Eimer S, Branger DF, Uro-Coste E, Labauge P.Long-term Outcomes of CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids) in a Consecutive Series of 12 Patients. Arch Neurol. 2012;69(7):847-55.
- Michel L, Foucher Y, Vukusic S, Confavreux C, de Sèze J, Brassat D, Clanet M, Clavelou P, Ouallet JC, Brochet B, Pelletier J, Labauge P, Lebrun C, Lepage E, Le Frere F, Jacq-Foucher M, Barriere P, Wiertlewski S, Laplaud DA. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry.2012, 83(8):796-802.
- Bine S, Haziot A, Malikova I, Pelletier J, Charron D, JBoucraut J, Mooney N and Gelin A. Alteration of CD1 expression in multiple sclerosis (pages 10–16). Clin ExpI Immunol 2012, 69(1):10-16.
- Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group (J. Pelletier, membre). Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11(5):420-8.
- Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler. 2012;18(12):1721-36.
- Wybrecht D, Reuter F, Zaaraoui W, Faivre A, Crespy L, Rico A, Malikova I, Confort-Gouny S, Soulier E, Cozzone PJ, Pelletier J, Ranjeva JP, Audoin B. Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis. Mult Scler. 2012, 18(11):1585-91.
- Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group (J. Pelletier, Membre). Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-9.
- Bourre B, Marignier R, Zéphir H, Papeix C, Brassat D, Castelnovo G, Collongues N, Vukusic S, Labauge P, Outteryck O, Fontaine B, Vermersch P, Confavreux C, de Seze J; NOMADMUS Study Group (J. Pelletier, Membre). Neuromyelitisoptica and pregnancy. Neurology. 2012;78(12):875-9.
- Durante L, Zaaraoui W, Rico A, Crespy L, Wybrecht D, Faivre A, Reuter F, Malikova I, Pommier G, Confort-Gouny S, Cozzone PJ, Ranjeva JP, Pelletier J, Boucraut J, Audoin B. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler. 2012;18(5):587-91.
- Baumstarck K, Pelletier J, Aghababian V, Reuter F, Klemina I, Berbis J, Loundou A, Auquier P.Is the concept of quality of life relevant for multiple sclerosis patients with cognitive impairment? Preliminary results of a cross-sectional study. PLoS One. 2012;7(1):e30627.

2010-2011

- Fernández O, Baumstarck-Barrau K, Simeoni MC, Auquier P; MusiQoL study group (J. Pelletier, Membre). Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler. 2011; 17(10): 1238-49.
- O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group (J. Pelletier, Membre). Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.
- Crespy L, Zaaraoui W, Lemaire M, Rico A, Faivre A, Reuter F, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP, Audoin B. Prevalence of grey matter pathology in early multiple sclerosis assessed by magnetization transfer ratio imaging. PLoS One. 2011;6(9):e24969.
- Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A, Malikova I, Soulier E, Viout P, Ranjeva JP, Pelletier J, Audoin B. Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(10):1157-9.
- Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group (J. Pelletier, Membre). Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 2011;77(9):835-43.
- International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, …, Pelletier J, …Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 10;476(7359):214-9.
- Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M; for The French–Italian Mitoxantrone Interferon-beta-1b Trial Group (J. Pelletier, Membre). Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year  randomised trial. J Neurol Neurosurg Psychiatry. 2011;82(12):1344-50.
- Collongues N, Cabre P, Marignier R, Zéphir H, Papeix C, Audoin B, Lebrun-Frenay C, Pelletier J, Fontaine B, Vermersch P, Confavreux C, de Seze J; Group Membres for NOMADMUS and CF-SEP. A benign form of neuromyelitis optica: does it exist? Arch Neurol. 2011;68(7):918-24.
- Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; on behalf of the TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520.
- Collongues N, Marignier R, Zéphir H, Blanc F, Vukusic S, Outteryck O, Fleury M, Ruet A, Borgel F, Thouvenot E, Moreau T, Defer G, Derache N, Pelletier J, Audoin B, Debouverie M, Labauge P, Gout O, Camu W, Brassat D, Brochet B, Vermersch P, Confavreux C, de Seze J. High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler. 2011;17(6):720-4.
- Zaaraoui W, Crespy L, Rico A, Faivre A, Soulier E, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP, Kaphan E, Audoin B. In vivo quantification of brain injury in adult Niemann-Pick Disease Type C. Mol Genet Metab. 2011;103(2):138-41.
- Le Page E, Leray E, Edan G, for the French Mitoxantrone Safety Group (J. Pelletier, Membre). Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 2011; 17(7):867-75.
- Gout O, Lebrun-Frenay C, Labauge P, Le Page GE, Clavelou P, Allouche S; PEDIAS Group (J. Pelletier, Membre).  Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event. J Neurol Neurosurg Psychiatry. 2011; 7(7):867-75.
- Reuter F, Zaaraoui W, Crespy L , Faivre A, Rico A1, Malikova I, Confort-Gouny S, Cozzone PJ, Ranjeva JP, Pelletier J, Audoin B. Cognitive impairment at the onset of multiple sclerosis: pattern and relationship to lesions location. Mult Scler 2011; 17(6):755-8.
- Zaaraoui W, Reuter F, Rico A, Faivre A, Crespy L, Malikova I, Soulier E, Viout P, Le Fur Y, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP, Audoin B. Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive deterioration. J Neurol. 2011;258(5):811-9.
- Rico A, Zaaraoui W, Franques J, Attarian S, Reuter F, Malikova I, Confort-Gouny S, Soulier E, Pouget J, Cozzone PJ, Pelletier J, Ranjeva JP, Audoin B. Motor cortical reorganization is present after a single attack of multiple sclerosis devoid of cortico-spinal dysfunction. MAGMA. 2011; 24(2):77-84.
- Zaaraoui W, Audoin B, Pelletier J, Cozzone PJ,  Ranjeva JP. Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. Biophys Rev 2010, 2:83–90.
- Reuter F, Baumstarck-Barrau K, Loundou A, Pelletier J, Auquier P. Paced auditory serial addition test: données normatives dans une population française. Rev Neurol (Paris).2010;166(11):944-7.
- Baumstarck-Barrau K, Pelletier J, Simeoni MC, Auquier P; et le MusiQol Study Group. Validation française du Multiple Sclerosis International Quality of Life Questionnaire (MusiQol).] Rev Neurol (Paris). 2011 2011;167(6-7):511-521.
- Baumstarck-Barrau K, Simeoni MC, Reuter F, Klemina I, Aghababian V, Pelletier J and Auquier P. Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional study. BMC Neurol. 2011 ;11(1):17.
- Kovalchin J, Krieger J, Genova M, Collins K, Augustyniak M, Masci A, Hittinger T, Kuca B, Edan G, Braudeau C, Rimbert M, Patel U, Mascioli E, Zanelli E (J. Pelletier, Membre). Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. J Neuroimmunol. 2010;225(1-2):153-63.
- Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW & SENTINEL Investigators (J. Pelletier, Membre). Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010;292(1-2):28-35.
- Collongues N, Marignier R, Zéphir H, Papeix C, Fontaine B, Blanc F, Rodriguez D, Fleury M, Vukusic S, Pelletier J, Audoin B, Thouvenot E, Camu W, Barroso B, Ruet A, Brochet B, Vermersch P, Confavreux C, de Seze J. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology. 2010;75(12):1084-8.
- Jure L, Zaaraoui W, Rousseau C, Reuter F, Rico A, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP, Audoin B. Individual voxel-based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis. J Magn Reson Imaging. 2010;32(2):424-8.
- Lebrun C, Blanc F, Brassat D, Zephir H, de Seze J & CFSEP (J. Pelletier, Membre). Cognitive function in radiologically isolated syndrome. Mult Scler. 2010;16(8):919-25.
- Zaaraoui W, Audoin B,  Pelletier J, Cozzone PJ,  Ranjeva JP. Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. Biophys Rev (2010) 2:83–90.
- Audoin B, Zaaraoui W, Reuter F, Rico A, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry, 2010, 81(6):690-5.
- Zaaraoui W, Rico A,  Audoin B, Reuter F,  Malikova I, Soulier E,  Viout P, Le Fur Y, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP. Unfolding the long term pathophysiological processes following an acute inflammatory demyelinating lesion of multiple sclerosis. Magn Reson Imaging. 2010, 28(4):477-86.
- Comi G, O'Connor,  Montalban PX, Antel J,  Radue EW,  Karlsson G, Pohlmann H, Aradhye S,  Kappos L for the FTY720D2201 Study Group (J. Pelletier, Membre).  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16(2):197-207.
- Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P & FREEDOMS Study Group (J. Pelletier, Membre). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362(5):387-401.
- Cohen JA,  Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L.  Oral Fingolimod vs Intramuscular Interferon in Relapsing Multiple Sclerosis. N Engl J Med. 2010, 362(5):402-15.
- Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Tchikviladzé M,  Ritleng C, Outteryck O, Vukusic S, Fleury O,  Mignot C, Fontaine B, Lyon-Caen O, Brassat D, Clanet M, Milh J, Pelletier J, Audoin B, et al. Neuromyelitis Optica in France: a Multicentric Study of 125 Patients. Neurology. 2010, 74(9):736-42.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). Variation within DNA repair pathway genes and risk of multiple sclerosis. Am J Epidemiol. 2010,172(2):217-24.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre).  Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. Nat Genet. 2010,42(6):469-70.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. Am J Hum Genet. 2010,86(4):621-5.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Hum Mol Genet. 2010 Jun 1;19(11):2331-40.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet. 2010,127(5):525-35.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet. 2010,19(5):953-62.

2008- 2009

- Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group (J. Pelletier, Membre). Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;(11):987-97.
- Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, Confavreux C (J. Pelletier, Membre). The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: Rationale, objectives and state of advancement. J Neurol Sci. 2009.
- Lebrun C, Bensa C, Debouverie M, Wiertlevski S, Brassat D, de Seze J, Rumbach L, Pelletier J, Labauge P, Brochet B, Tourbah A, Clavelou P; Club Francophone de la Sclérose en Plaques. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol. 2009, 66:841-6.
- Pelletier J, Audoin B, Reuter F, Ranjeva J. Plasticity in MS: from Functional Imaging to Rehabilitation. Int MS J. 2009, 16:26-31.
- Rico A, Audoin B, Franques J, Eusebio A, Reuter F, Malikova I, Ali Cherif A, Pouget J, Pelletier J and Attarian S. Motor evoked potentials in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2009, 15:355-62.
- O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group (J. Pelletier, Membre). Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology, 2009,72:73-9.
- De Stefano N, Filippi M, Confavreux C, Vermersch P, Simu M, Sindic C, Hupperts R, Bajenaru O, Edan G, Grimaldi L, Marginean I, Medaer R, Orefice G, Pascu I, Pelletier J, Sanders E, Scarpini E, Mancardi G. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009,15:238-43.
- Desplat-Jégo S, Feuillet L, Creidy R, Malikova I, Rance R, Khrestchatisky M, Hahm K, Burkly LC, Pelletier J and Boucraut J.TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol. 2009,85:132-5.Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The Onset Location of Multiple Sclerosis Predicts the Location of Subsequent Relapses. J Neurol Neurosurg Psychiatry 2009, 80(4):400-3.
- Reuter F, Del Cul A, Malikova I, Naccache L, Confort-Gouny S, Cohen L, Cherif AA, Cozzone PJ, Pelletier J, Ranjeva JP, Dehaene S, Audoin B. White matter damage impairs access to consciousness in multiple sclerosis. Neuroimage. 2009,44:590-9.
- International MS Genetics Consortium (IMSGC) (J. Pelletier, Membre). Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009,41(7):776-82.
- International MS Genetics Consortium (IMSGC) (J. Pelletier, Membre).  IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009,5(1):e1000322.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 2009,10(1):11-4.
- International Multiple Sclerosis Genetics Consortium (IMSGC) (J. Pelletier, Membre). CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 2009,10(1):5-10.
- Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM & REGARD study group. (J. Pelletier, Membre). Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008, 7:903-14.
- Pelletier J, Audoin B, Reuter F, Malikova I, Rico A, Chérif AA, Ranjeva JP, Cozzone P. Cerebral plasticity and multiple sclerosis: data from functional imaging] Rev Neurol (Paris). 2008,164 (S2):F147-53.
- Audoin B, Reuter F, Duong MV, Malikova I, Confort-Gouny S, Cherif AA, Cozzone PJ, Pelletier J and Ranjeva JP. Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. Mult Scler. 2008,14:786-92.
- Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay. Clin Chim Acta. 2008,391:98-101.
- Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R & BENEFIT investigators (J. Pelletier, Membre). Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol. 2008,255:480-7.
- Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J; MusiQol study group. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008,14:219-30.
- Mikaeloff Y, Caridade G, Tardieu M, Suissa S; KIDSEP study group of the French Neuropediatric Society (J. Pelletier, Membre). Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol. 2008,12:205-9.

2006-2007

- Reuter F, Del Cul A, Audoin B, Malikova I, Naccache L, Ranjeva JP, Lyon-Caen O, Ali Chérif A, Cohen L, Dehaene S, Pelletier J. Intact subliminal processing and delayed conscious access in multiple sclerosis. Neuropsychologia. 2007, 45:2683–2691.
- Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, Pelletier J and Cozzone PJ. Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS ONE. 2007;2:e595.
- Audoin B, Guye M, Reuter F, Au Duong MV, Confort-Gouny S, Malikova I, Soulier E, Viout P, Cherif AA, Cozzone PJ, Pelletier J and Ranjeva JP.Structure of WM bundles constituting the working memory system in early multiple sclerosis: A quantitative DTI tractography study. Neuroimage 2007, 36(4):1324-1330.
- Au Duong MV, Audoin B, Le Fur Y, Confort-Gouny S,  Mailkova I,  Soulier E, Viout P, Ali Chérif A, Pelletier J, Cozzone PJ, Ranjeva JP. Relationships between grey matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS. A MRSI study.  J Neurol. 2007, 254(7):914-23.
- Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, Pelletier J.Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2007;13:124-7.
- Audoin B, Ibarrola D, Malikova I, Soulier E, Confort-Gouny S, Duong MV, Reuter F, Viout P, Ali-Cherif A, Cozzone PJ, Pelletier J and Ranjeva JP. Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis--a two-year longitudinal MrI/MRSI study of corpus callosum. Mult Scler. 2007;13:41-51.
- Lutz NW, Viola A, Malikova I, Confort-Gouny S, Ranjeva JP, Pelletier J, Cozzone PJ. A branched-chain organic acid linked to multiple sclerosis: First identification by NMR spectroscopy of CSF. Biochem Biophys Res Commun. 2007;354:160-4.
- de Seze J, Debouverie M, Zephir H, Lebrun C, Blanc F, Bourg V, Wiertlewski S, Pittion S, Laplaud D, Le Page E, Deschamps R, Cabre P, Pelletier J, Malikova I, Clavelou P, Jaillon V, Defer G, Labauge P, Gout O, Boulay C, Edan G, Vermersch P. Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients. Arch Neurol. 2007, 64(10):1426-1432.
- Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C; Adult Neurology Departments KIDMUS Study Group.Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007, 356(25):2603-13.
- Feuillet L, Pelletier J, Suchet L, Rico A, Ali Cherif A, Pouget J, and Attarian S.  Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study. Mult Scler 2007 13: 348-356.
- Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators (J. Pelletier Membre). MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007,68(17):1390-401.
- Audoin B, Au Duong MV, Malikova I, Confort-Gouny S, Ibarrola D, Cozzone PJ, Pelletier J and Ranjeva JP. Functional magnetic resonance imaging and cognition at the very early stage of MS. J Neurol Sci. 2006, 245:87-91.
- Ranjeva JP, Audoin B, Au Duong MV, Confort-Gouny S, Malikova I, Viout P, Soulier E, Pelletier J and14.48+ Cozzone PJ. Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J Neurol Sci. 2006, 245:161-7.
- Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R for the BENEFIT Study Group (J. Pelletier, membre).Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006, 67:1242-9.
- Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group.Oral fingolimod (FTY720) for relapsing multiple sclerosis (J. Pelletier, membre). N Engl J Med. 2006, 355:1124-40.
- Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW and the SENTINEL Investigators (J. Pelletier, membre). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006, 354:911-23.
- O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group(J. Pelletier, membre). A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006, 66:894-900.
- Filippi M, Wolinsky JS, Comi G; CORAL Study Group (J. Pelletier, membre). Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2006;5(3):213-20.
- Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators (J. Pelletier, membre). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.

2004-2005

- Au Duong MV, Audoin B, Boulanouar, K, Ibarrola D, Malikova I, Confort-Gouny S, Celcis, P, Cozzone PJ, Pelletier J and Ranjeva JP. Altered functional connectivity related to white matter changes inside the working memory network at the very early stage of MS. J Cereb Blood Flow Metab. 2005, 25:1245-53.
- De Seze J, Lanctin C, Lebrun C, Malikova I, Papeix C, Wiertlewski S, Pelletier J, Gout O, Clerc C, Moreau C, Defer G, Edan G, Dubas F, Vermersch P.Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology. 2005, 65:1950-3.
- Desplat-Jégo S, Feuillet L, Pelletier J, Bernard ARD, Ali Chérif A, Boucraut J. Quantification of the free light chains in the CSF by nephelemetry in multiple sclerosis. J Clin Immunolgy 2005, 25:338-345.
- Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M, French Modafinil Study Group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005, 64:1139-43.
- Freedman MS, Francis GS, Sanders EA, Rice GP, O'Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, Abramsky O, Pelletier J, O'Brien F; Once Weekly Interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler. 2005, 11:41-5.
- Audoin B, Ibarrola D, Duong MV, Pelletier J, Confort-Gouny S, Malikova I, Ali-Cherif A, Cozzone PJ, Ranjeva JP. Functional MRI study of PASAT in normal subjects. MAGMA. 2005, 18:96-102.
- Ranjeva JP, Audoin B, Duong MV, Ibarrola D, Confort-Gouny S, Malikova I, Soulier E, Viout P, Ali-Cherif A, Pelletier J and Cozzone P. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR. 2005, 26:119-27.
- Au Duong MV, Boulanouar K, Audoin B, Treseras S, Ibarrola D, Malikova I, Confort-Gouny S, Celsis P, Pelletier J, Cozzone PJ, Ranjeva JP. Modulation of effective connectivity inside the working memory network in patients at the earliest stage of multiple sclerosis. Neuroimage. 2005, 24:533-8.
- Audoin B, Van Au Duong M, Ranjeva JP, Ibarrola D, Malikova I, Confort-Gouny S, Soulier E, Viout P, Ali-Cherif A, Pelletier J and Cozzone PJ. Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. Hum Brain Mapp. 2005, 24:216-28.
- Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L & the European IFN-1a in Relapsing MS Dose Comparison Trial Study Group (J. Pelletier Membre). Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005, 64:236-40.
- Audoin B, Ranjeva JP, Duong MV, Ibarrola D, Malikova I, Confort-Gouny S, Soulier E, Viout P, Ali-Cherif A, Pelletier J and Cozzone PJ. Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging. 2004, 20:765-71.
- Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, Confavreux C, Tardieu M; KIDMUS Study Group (J. Pelletier membre). First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004, 144:246-52.
- Mikaeloff Y, Adamsbaum C, Husson B, Vallee L, Ponsot G, Confavreux C, Tardieu M, Suissa S; KIDMUS Study Group on Radiology (J. Pelletier Membre). MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood.  Brain. 2004, 127:1942-7.
- Zephir H, De Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Senechal O, Vermersch P.Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.  J Neurol Sci. 2004, 218:73-7.
- Audoin B, Ibarrola D, Ranjeva JP, Confort-Gouny S, Malikova I, Ali-Cherif A, Pelletier J and Cozzone P. Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Hum Brain Mapp. 2003, 20:51-8.
- Ranjeva JP, Pelletier J, Confort-Gouny S, Ibarrola D, Audoin B, Le Fur Y, Viout P, Cherif AA, Cozzone PJ. MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2003, 9:554-65.
- Clanet M, Kappos L, Hartung HP, Hohlfeld R; European IFNbeta-1a Dose-Comparison Study Investigators (J. Pelletier, membre). Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler. 2004;10(2):139-44.

2001-2003

- Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans-Coutinho M, Clanet M, Radue EW, Kappos L; European rIFN beta-1a in Relapsing MS Dose Comparison Trial Study Group (J. Pelletier, membre). Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. Arch Neurol. 2003;60(12):1736-9.
- Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group (J. Pelletier, membre). Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler. 2003;9(4):342-8.
- Granel B, Serratrice J, Pelletier J, Reviron D, Disdier P, Weiller PJ. Antiphospholipid syndrome in husband and wife and multiple sclerosis in the daughter. Presse Med 2002, 12: 23.
- Pelletier J, Laguitton V, Roux-Parra F, Audouin B, Ranjeva JP, Confort-Gouny S, Ali Chérif A, Cozzone PJ.Cognitive and Emotional status in a population of Patients presented with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis. Mult Scler 2002, 8:S95.
- Pelletier J, Audouin B, Suchet L, Ranjeva JP, Confort-Gouny S, Cozzone PJ, Ali Chérif A. A prospective study of multiple sclerosis presenting with large focal tumor-like lesions of the brain. Mult Scler 2002, 8:S32.
- Pelletier J, Audouin B, Ranjeva JP, Suchet L, Dalecky A, Confort-Gouny S, Cozzone PJ, Ali Chérif A. Mult Scler 2002, 8:S33.
- Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW, and the European IFN{beta}-1a (Avonex) Dose-Comparison Study Investigators (J. Pelletier, membre). A randomized, double-blind, dose-comparison study of weekly interferon {beta}-1a in relapsing MS. Neurology 2002; 59: 1507.
- Granel B, Serratrice J, Pelletier J, Reviron D, Disdier P, Weiller PJ. Antiphospholipid syndrome in husband and wife and multiple sclerosis in the daughter. Presse Med 2002, 12: 23.
- Pelletier J, Suchet L, Witjas, T Habib M, Guttmann C,  Salamon G, Lyon-Caen O, Ali Chérif A. A longitudinal study of callosal atrophy in relapsing-remitting multiple sclerosis. Arch Neurol, 2001, 58 :105-111. 10.03.
- Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, Ranoux D, Pelletier J, Figarella-Branger D, Granel B, Maisonobe T, Coquet M, Degos JD, Gherardi RK.Demyelinating central nervous system disease in patients with macrophagic myofasciitis. Brain. 2001,124:974-83. The SPECTRIMS Study Group (J. Pelletier membre).  Randomized trial of interferon-ك-1a in secondary progressive multiple sclerosis: clinical results of the SPECTRIMS study. Neurology, 2001, 56 : 1496-1504.
- The SPECTRIMS S

Comment accéder au centre ?

Conformément à la législation relative à la protection des données, nous vous informons que ce site utilise des cookies à des fins de statistiques. En cliquant sur le bouton 'Accepter', vous autorisez les services tiers que nous utilisons à éventuellement déposer un ou plusieurs cookies sur votre ordinateur. Pour en savoir plus, consultez nos mentions légales